Publicacións en colaboración con investigadores/as de Hospital Clínico San Carlos de Madrid (22)

2011

  1. Analysis of the influence of the ghrelin receptor rs509035, rs512692 and rs2922126 polymorphisms in the risk of cardiovascular disease in patients with rheumatoid arthritis

    Clinical and Experimental Rheumatology

  2. CCR5Δ32 variant and cardiovascular disease in patients with rheumatoid arthritis: A cohort study

    Arthritis Research and Therapy, Vol. 13, Núm. 4

  3. Lack of association between ADIPOQ rs266729 and ADIPOQ rs1501299 polymorphisms and cardiovascular disease in rheumatoid arthritis patients

    Tissue Antigens, Vol. 77, Núm. 1, pp. 74-78

  4. Lack of association between LEP rs2167270 (19 G>A) polymorphism and disease susceptibility and cardiovascular disease in patients with rheumatoid arthritis

    Clinical and Experimental Rheumatology, Vol. 29, Núm. 2, pp. 293-298

  5. Lack of association between RETN rs1862513 polymorphism and cardiovascular disease in patients with rheumatoid arthritis

    Clinical and Experimental Rheumatology, Vol. 29, Núm. 1, pp. 19-25

  6. Lack of association of NAMPT rs9770242 and rs59744560 polymorphisms with disease susceptibility and cardiovascular risk in patients with rheumatoid arthritis

    Clinical and Experimental Rheumatology, Vol. 29, Núm. 4, pp. 681-688

  7. Role of the rs6822844 gene polymorphism at the IL2-IL21 region in biopsy-proven giant cell arteritis

    Clinical and Experimental Rheumatology, Vol. 29, Núm. 1 SUPPL. 64

  8. TNFA -308 (rs1800629) polymorphism is associated with a higher risk of cardiovascular disease in patients with rheumatoid arthritis

    Atherosclerosis, Vol. 216, Núm. 1, pp. 125-130

  9. Vascular endothelial growth factor A and cardiovascular disease in rheumatoid arthritis patients

    Tissue Antigens, Vol. 77, Núm. 4, pp. 291-297

2010

  1. A1298C polymorphism in the MTHFR gene predisposes to cardiovascular risk in rheumatoid arthritis

    Arthritis Research and Therapy, Vol. 12, Núm. 2

  2. Association between IL-18 gene polymorphisms and biopsy-proven giant cell arteritis

    Arthritis Research and Therapy, Vol. 12, Núm. 2

  3. Influence of CD40 rs1883832 polymorphism in susceptibility to and clinical manifestations of biopsy-proven giant cell arteritis

    Journal of Rheumatology, Vol. 37, Núm. 10, pp. 2076-2080

  4. Lack of association between IFNGR1 gene polymorphisms and biopsy-proven giant cell arteritis

    Clinical and Experimental Rheumatology, Vol. 28, Núm. 1 SUPPL. 57

  5. Lack of association between IRF5 gene polymorphisms and biopsy-proven giant cell arteritis

    Journal of Rheumatology, Vol. 37, Núm. 1, pp. 136-140

  6. Lack of association between TRAF1/C5 gene polymorphisms and biopsy-proven giant cell arteritis

    Journal of Rheumatology, Vol. 37, Núm. 1, pp. 131-135

  7. Lack of association between hypoxia inducible factor-1 alpha gene polymorphisms and biopsy-proven giant cell arteritis

    Clinical and Experimental Rheumatology, Vol. 28, Núm. 1 SUPPL. 57

  8. Lack of association between the rs6920220 (G/A) polymorphism of the 6q23 region and biopsy-proven giant cell arteritis

    Journal of Rheumatology, Vol. 37, Núm. 5, pp. 1020-1023

  9. Lack of association of PTPN22, STAT4 and TRAF1/C5 gene polymorphisms with cardiovascular risk in rheumatoid arthritis

    Clinical and Experimental Rheumatology, Vol. 28, Núm. 5, pp. 695-701

  10. Role of BANK1 gene polymorphisms in biopsy-proven giant cell arteritis

    Journal of Rheumatology, Vol. 37, Núm. 7, pp. 1502-1504

  11. Role of the C8orf13-BLK region in biopsy-proven giant cell arteritis

    Human Immunology, Vol. 71, Núm. 5, pp. 525-529